# Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02863328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02863328](<https://clinicaltrials.gov/study/NCT02863328>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02863328

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 822 participants.

## Technical summary

Registry record NCT02863328. Randomized; no masking; primary purpose treatment. Start 2016-08-10 (actual); primary completion 2017-08-01 (actual). Results posted on 2019-12-24.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 822 participants (enrolled count; ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Started: 2016-08-10 (actual) (ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Primary completion: 2017-08-01 (actual) (ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Completion: 2018-03-08 (actual) (ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Results first posted: 2019-12-24 (ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Croatia; Greece; Hungary; Italy; Poland; Russia; Serbia; Spain; Thailand (ClinicalTrials.gov record NCT02863328, source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02863328-2022-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Acronym: PIONEER 2
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): empagliflozin
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial (`cardio:pubmed-31530666`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c198b12d492056bea4620c382c66489e6406ff4739263daecd7f29dfca086b5b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
